Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Relapsed or Refractory Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Their Standard Therapy

NCT01794507 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT01794507
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01794507 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Relapsed or Refractory Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Their Standard Therapy
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Completed
Start date
November 19, 2012
Completion date
July 16, 2019
Enrollment
66 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory multiple myeloma